Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 22:13:1166775.
doi: 10.3389/fonc.2023.1166775. eCollection 2023.

Ablation treatment of hepatocellular carcinoma: a bibliometric analysis

Jianping Song  1 , Tingxiao Zhang  2 , Jianlei Wang  2 , Yanfeng Liu  3
Affiliations

Ablation treatment of hepatocellular carcinoma: a bibliometric analysis

Jianping Song et al. Front Oncol. .

Abstract

Objective: Ablation is a common treatment for hepatocellular carcinoma (HCC). This study aimed to assess research trends in the ablation treatment of HCC using bibliometric analysis.

Methods: Publications between January 1, 1993 and December 31, 2022 were retrieved from the Web of Science database. The bibliometrix package from R software, CiteSpace, VOSviewer and an online analytical platform were used for data analysis and plotting.

Results: A total of 4,029 publications were retrieved from the Web of Science database between 1993 and 2022. The annual growth rate of publication numbers was 10.14%. China had the largest number of publications in the field of HCC ablation. China and the United States of America have the most notable cooperation. Sun Yat-sen University had the largest number of publications in the field of HCC ablation. The most relevant journals were Hepatology, Journal of Hepatology, Gastroenterology, and Radiology. High-frequency keywords mainly focused on "therapy," "resection," "radiofrequency ablation" and "survival".

Conclusions: With the increase in related publications, the research direction of ablation treatment of HCC is mainly focused on "therapy," "resection," "radiofrequency ablation" and "survival", and the ablation treatment method has gradually changed from percutaneous ethanol injection to radiofrequency ablation and microwave ablation. Irreversible electroporation may become the main method of ablation therapy in the future.

Keywords: Bibliometrix; Citespace; VOSviewer; ablation; bibliometric analysis; hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Trend of annual publication and citation numbers for ablation therapy of HCC from 1993 to 2022.
Figure 2
Figure 2
Countries/regions distribution and collaboration network.
Figure 3
Figure 3
(A) Network visualization map of co-authorship institutions related to ablation treatment of hepatocellular carcinoma created by VOSviewer. (B) Network visualization map of co-cited journals related to ablation treatment of hepatocellular carcinoma created by VOSviewer.
Figure 4
Figure 4
(A) Network visualization map of co-cited authors related to ablation treatment of hepatocellular carcinoma created by VOSviewer. (B) Network visualization map of co-cited references related to ablation treatment of hepatocellular carcinoma created by VOSviewer.
Figure 5
Figure 5
(A) The most common keywords in HCC ablation research. The brightness of each node represents the frequency of keywords. (B) Overlay visualization map of co-occurring keywords. The color of each node represents the average appearing year for the keyword, depending on the color gradient shown at the bottom. (C) The top 40 keywords with the strongest citation bursts during 1993–2022 (generated by CiteSpace).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. . Hepatocellular carcinoma. Nat Rev Dis Primers. (2016) 2:16018. doi: 10.1038/nrdp.2016.18 - DOI - PubMed
    1. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol (2018) 48(2):103–14. doi: 10.1093/jjco/hyx180 - DOI - PubMed
    1. da Fonseca LG, Araujo R. Combination approaches in hepatocellular carcinoma: how systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol (2022) 28(28):3573–85. doi: 10.3748/wjg.v28.i28.3573 - DOI - PMC - PubMed
    1. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. (2009) 49(2):453–9. doi: 10.1002/hep.22648 - DOI - PubMed
    1. Weinstein JL, Ahmed M. Percutaneous ablation for hepatocellular carcinoma. AJR Am J Roentgenol. (2018) 210(6):1368–75. doi: 10.2214/AJR.17.18695 - DOI - PubMed

LinkOut - more resources